CDT Equity (CDT) Free Cash Flow (2022 - 2026)
CDT Equity's (CDT) quarterly Free Cash Flow came in at -$1.9 million in Q1 2026, up 56.29% YoY from -$1.2 million in Q1 2025, and up 59.31% on a QoQ basis from -$4.7 million in Q4 2025.
CDT Equity (CDT) Free Cash Flow (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 5 years of Free Cash Flow data on file, last reported at -$1.9 million in Q1 2026.
- Quarterly Free Cash Flow rose 56.29% year-over-year to -$1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.5 million (down 15.94% YoY) and the FY2025 annual result came in at -$15.6 million, down 59.82% from the prior year.
- Free Cash Flow climbed to -$1.9 million in Q1 2026, from -$4.7 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$126915.0 in Q2 2022 to a low of -$4.8 million in Q4 2023.
- A 5-year average of -$2.2 million and a median of -$2.0 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow slumped 433.33% — and 2026, when it soared 56.29%.
- Tracing CDT's Free Cash Flow over 5 years: stood at -$900000.0 in 2022, then tumbled by 433.33% to -$4.8 million in 2023, then advanced by 21.21% to -$3.8 million in 2024, then slipped by 23.08% to -$4.7 million in 2025, then surged by 59.31% to -$1.9 million in 2026.
- The last three Free Cash Flow figures came in at -$1.9 million (Q1 2026), -$4.7 million (Q4 2025), and -$4.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | -4.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.34 Mn |
| Jun 30, 2026 | -4.34 Mn |
| Mar 31, 2026 | -1.89 Mn |
| Mar 31, 2026 | -1.89 Mn |
| Dec 31, 2025 | -4.66 Mn |
| Dec 31, 2025 | -4.66 Mn |
| Sep 30, 2025 | -4.39 Mn |
| Sep 30, 2025 | -4.39 Mn |
| Jun 30, 2025 | -2.57 Mn |
| Jun 30, 2025 | -2.57 Mn |
| Mar 31, 2025 | -4.33 Mn |
| Mar 31, 2025 | -4.33 Mn |
| Dec 31, 2024 | -3.78 Mn |
| Dec 31, 2024 | -3.78 Mn |
| Sep 30, 2024 | -2.04 Mn |
| Sep 30, 2024 | -2.04 Mn |
| Jun 30, 2024 | -1.50 Mn |
| Jun 30, 2024 | -1.50 Mn |
| Mar 31, 2024 | -2.40 Mn |
| Mar 31, 2024 | -2.40 Mn |